Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma.

Enblad G, Karlsson H, Loskog AS.

Hum Gene Ther. 2015 Aug;26(8):498-505. doi: 10.1089/hum.2015.054. Review.

2.

Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity.

Rodríguez-García A, Svensson E, Gil-Hoyos R, Fajardo CA, Rojas LA, Arias-Badia M, Loskog AS, Alemany R.

Gene Ther. 2015 Jul;22(7):596-601. doi: 10.1038/gt.2015.41. Epub 2015 May 21.

PMID:
25994521
3.

The cerebrospinal fluid cytokine signature of multiple sclerosis: a homogenous response that does not conform to the Th1/Th2/Th17 convention.

Burman J, Svensson E, Fransson M, Loskog AS, Zetterberg H, Raininko R, Svenningsson A, Fagius J, Mangsbo SM.

J Neuroimmunol. 2014 Dec 15;277(1-2):153-9. doi: 10.1016/j.jneuroim.2014.10.005. Epub 2014 Oct 18.

PMID:
25457841
4.

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.

Sandin LC, Eriksson F, Ellmark P, Loskog AS, Tötterman TH, Mangsbo SM.

Oncoimmunology. 2014 Jan 1;3(1):e27614. Epub 2014 Jan 16.

5.

Intranasal delivery of central nervous system-retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis.

Fransson M, Piras E, Wang H, Burman J, Duprez I, Harris RA, LeBlanc K, Magnusson PU, Brittebo E, Loskog AS.

Immunology. 2014 Jul;142(3):431-41. doi: 10.1111/imm.12275.

6.

Assessing tissue damage in multiple sclerosis: a biomarker approach.

Burman J, Zetterberg H, Fransson M, Loskog AS, Raininko R, Fagius J.

Acta Neurol Scand. 2014 Aug;130(2):81-9. doi: 10.1111/ane.12239. Epub 2014 Feb 24.

PMID:
24571714
7.

CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes.

Liljenfeldt L, Dieterich LC, Dimberg A, Mangsbo SM, Loskog AS.

Cancer Gene Ther. 2014 Mar;21(3):95-102. doi: 10.1038/cgt.2014.2. Epub 2014 Jan 31.

PMID:
24481488
8.

Enhanced therapeutic anti-tumor immunity induced by co-administration of 5-fluorouracil and adenovirus expressing CD40 ligand.

Liljenfeldt L, Gkirtzimanaki K, Vyrla D, Svensson E, Loskog AS, Eliopoulos AG.

Cancer Immunol Immunother. 2014 Mar;63(3):273-82. doi: 10.1007/s00262-013-1507-6. Epub 2013 Dec 20.

PMID:
24357147
9.

Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma.

Westberg S, Sadeghi A, Svensson E, Segall T, Dimopoulou M, Korsgren O, Hemminki A, Loskog AS, Tötterman TH, von Euler H.

J Immunother. 2013 Jul-Aug;36(6):350-8. doi: 10.1097/CJI.0b013e31829d8a1b.

PMID:
23799414
10.

T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis.

Burman J, Fransson M, Tötterman TH, Fagius J, Mangsbo SM, Loskog AS.

Immunology. 2013 Oct;140(2):211-9. doi: 10.1111/imm.12129.

11.

Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia.

Christiansson L, Söderlund S, Svensson E, Mustjoki S, Bengtsson M, Simonsson B, Olsson-Strömberg U, Loskog AS.

PLoS One. 2013;8(1):e55818. doi: 10.1371/journal.pone.0055818. Epub 2013 Jan 31.

12.

Genetically engineered T cells for the treatment of cancer.

Essand M, Loskog AS.

J Intern Med. 2013 Feb;273(2):166-81. doi: 10.1111/joim.12020. Review.

13.

AdCD40L--crossing the valley of death?

Ullenhag G, Loskog AS.

Int Rev Immunol. 2012 Aug;31(4):289-98. doi: 10.3109/08830185.2012.692844. Review.

PMID:
22804573
14.

CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery.

Fransson M, Piras E, Burman J, Nilsson B, Essand M, Lu B, Harris RA, Magnusson PU, Brittebo E, Loskog AS.

J Neuroinflammation. 2012 May 30;9:112. doi: 10.1186/1742-2094-9-112.

15.

Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.

Diaconu I, Cerullo V, Hirvinen ML, Escutenaire S, Ugolini M, Pesonen SK, Bramante S, Parviainen S, Kanerva A, Loskog AS, Eliopoulos AG, Pesonen S, Hemminki A.

Cancer Res. 2012 May 1;72(9):2327-38. doi: 10.1158/0008-5472.CAN-11-2975. Epub 2012 Mar 6.

16.

T regulatory cells in B-cell malignancy - tumour support or kiss of death?

Lindqvist CA, Loskog AS.

Immunology. 2012 Apr;135(4):255-60. doi: 10.1111/j.1365-2567.2011.03539.x. Review.

17.

Both CD4+ FoxP3+ and CD4+ FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro.

Lindqvist CA, Christiansson LH, Thörn I, Mangsbo S, Paul-Wetterberg G, Sundström C, Tötterman TH, Simonsson B, Enblad G, Frisk P, Olsson-Strömberg U, Loskog AS.

Immunology. 2011 Jul;133(3):296-306. doi: 10.1111/j.1365-2567.2011.03439.x. Epub 2011 Apr 5.

18.

T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies.

Lindqvist CA, Christiansson LH, Simonsson B, Enblad G, Olsson-Strömberg U, Loskog AS.

Immunology. 2010 Nov;131(3):371-6. doi: 10.1111/j.1365-2567.2010.03308.x.

19.

AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial.

Malmström PU, Loskog AS, Lindqvist CA, Mangsbo SM, Fransson M, Wanders A, Gårdmark T, Tötterman TH.

Clin Cancer Res. 2010 Jun 15;16(12):3279-87. doi: 10.1158/1078-0432.CCR-10-0385. Epub 2010 May 4.

20.

Complement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effects.

Mangsbo SM, Sanchez J, Anger K, Lambris JD, Ekdahl KN, Loskog AS, Nilsson B, Tötterman TH.

J Immunol. 2009 Nov 15;183(10):6724-32. doi: 10.4049/jimmunol.0902374. Epub 2009 Oct 28.

21.

The Janus faces of CD40 in cancer.

Loskog AS, Eliopoulos AG.

Semin Immunol. 2009 Oct;21(5):301-7. doi: 10.1016/j.smim.2009.07.001. Epub 2009 Jul 31. Review.

PMID:
19647448
22.

Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas.

Vardouli L, Lindqvist C, Vlahou K, Loskog AS, Eliopoulos AG.

Cancer Gene Ther. 2009 Nov;16(11):848-60. doi: 10.1038/cgt.2009.31. Epub 2009 May 22.

PMID:
19461675
23.

The T-cell pool is anergized in patients with multiple sclerosis in remission.

Fransson ME, Liljenfeldt LS, Fagius J, Tötterman TH, Loskog AS.

Immunology. 2009 Jan;126(1):92-101. doi: 10.1111/j.1365-2567.2008.02881.x. Epub 2008 Jun 24.

24.

AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model.

Loskog AS, Fransson ME, Totterman TT.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8816-21.

Supplemental Content

Loading ...
Support Center